<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pulmonary alveolar proteinosis in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pulmonary alveolar proteinosis in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pulmonary alveolar proteinosis in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher Towe, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David R Spielberg, MD, MHSc
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Chmiel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary alveolar proteinosis (PAP) is characterized by the accumulation of surfactant within alveoli, with highly variable prognosis and multiple etiologies. In adults, it is usually caused by an autoimmune process that interferes with surfactant recycling. In infants and children, PAP is usually caused by different mechanisms, and most cases involve genetic or acquired defects in surfactant metabolism, leading to excessive accumulation of surfactant in the alveoli [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The pathogenesis, clinical features, and treatment of PAP in infants and children are discussed in this topic review. PAP in adults has different causes and clinical manifestations and is discussed in separate topic reviews. In some older children, the disorder may be similar to the form seen in adults. (See
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Four forms of PAP are recognized in children: congenital, primary (encompassing autoimmune and hereditary PAP), secondary, and idiopathic  (
         <a class="graphic graphic_table graphicRef77313" href="/z/d/graphic/77313.html" rel="external">
          table 1
         </a>
         ). The common characteristic is the accumulation of pulmonary surfactants in the alveolar space, which can be due to altered surfactant production, removal, or both [
         <a href="#rid2">
          2
         </a>
         ]. In infants and young children, PAP is most frequently caused by inborn errors of surfactant metabolism or immune deficiencies, whereas the vast majority of cases in adults are autoimmune  (
         <a class="graphic graphic_figure graphicRef115856" href="/z/d/graphic/115856.html" rel="external">
          figure 1
         </a>
         ). All forms of PAP in children are rare, and there are limited data on the overall incidence or prevalence of PAP in children. One large study of PAP utilizing a United States insurance database estimated an annual prevalence of approximately 2 cases per 1 million among individuals under 18 years of age [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Congenital form
         </span>
         <span class="headingEndMark">
          —
         </span>
         A range of genetic disorders may result in PAP. Most cases present during the neonatal period or early infancy, although some forms occasionally present later. This form of PAP is sometimes referred to as congenital PAP, although this terminology may pose confusion in distinguishing congenital versus hereditary PAP because both have genetic causes. (See
         <a class="local">
          'Hereditary PAP'
         </a>
         below.)
        </p>
        <p>
         For most of the congenital forms of PAP, the histopathologic manifestations are primarily interstitial changes, often with a relatively minor component of alveolar proteinosis. By contrast, alveolar proteinosis is prominent in primary PAP. (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p>
         These disorders include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inborn errors of surfactant metabolism
         </strong>
         – Genetic surfactant dysfunction disorders are caused by mutations in genes encoding proteins critical for the production and function of pulmonary surfactant. These rare disorders may produce familial or sporadic lung disease with clinical presentations ranging from neonatal respiratory failure to childhood- or adult-onset interstitial lung disease. These disorders are caused by deficiencies or dysfunction in surfactant proteins, due to variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178640&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWBYvxs5%2BwVZVSC5f9ekAfQ7&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPB
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178620&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWA5xwZuJaSzQofzVsf1R0ZE&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPC
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601615&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAvN5Ym0VFBwBqjZPN6uIc&amp;TOPIC_ID=6351" target="_blank">
          <i>
           ABCA3
          </i>
         </a>
         , or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=6351" target="_blank">
          <i>
           NKX2.1
          </i>
          /
          <i>
           TTF1
          </i>
         </a>
         . These disorders are discussed in detail in a separate topic review. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lysinuric protein intolerance (LPI)
         </strong>
         – LPI (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F222700&amp;token=tEpDslnpc0F0kICl%2Fz7sFRJcCUASk49Ds%2FQL7Yc%2FaUWJbUNB2ryoL3ST3JzqLy7v&amp;TOPIC_ID=6351" target="_blank">
          MIM #222700
         </a>
         ) is an autosomal recessive disorder caused by defective plasma membrane transport of the cationic amino acids, lysine, arginine, and ornithine [
         <a href="#rid4">
          4,5
         </a>
         ]. LPI results from mutations or disruptions in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603593&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypPLCxuS%2Fh96C9M4Y0WASei&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SLC7A7
          </i>
         </a>
         gene, which encodes the light chain of the cationic amino acid transporter y+ [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The clinical manifestations of LPI can be multisystemic and include failure to thrive, anorexia, vomiting, diarrhea, lethargy, and coma. Patients can present from the neonatal period to adulthood. Abnormalities of the liver, spleen, pancreas, kidney, bone marrow, and brain may be seen [
         <a href="#rid7">
          7,8
         </a>
         ]. Not all children with LPI develop PAP. Respiratory manifestations can present as progressive respiratory distress leading to frank respiratory failure that can become life threatening [
         <a href="#rid9">
          9
         </a>
         ]. Children with LPI who develop PAP often die, and recurrence of disease following heart-lung transplantation has been reported with fatal consequences [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="local">
          'Congenital PAP'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interstitial lung and liver disease (La Réunion)
         </strong>
         – Pulmonary disease due mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F156560&amp;token=87jLzclRwWxNoI%2BQq5Gg7wF6gM8Gns%2Bz2A%2BrNCIR2sEDqWlxRamT%2BT2RQgezWobe&amp;TOPIC_ID=6351" target="_blank">
          <i>
           MARS1
          </i>
         </a>
         gene has been reported in a few clusters (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F615486&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2BfBn93DbhoFFHSCv28ux55Xwjti0mBHWx2IMmre7ML4&amp;TOPIC_ID=6351" target="_blank">
          MIM #615486
         </a>
         ), primarily in the region of La Réunion island [
         <a href="#rid10">
          10
         </a>
         ]. Because this gene is expressed in tissues other than the lung, infants with these disorders manifest symptoms related to other organ systems. The pulmonary disease starts in infancy and may progress to pulmonary fibrosis with cholesterol granulomas [
         <a href="#rid11">
          11
         </a>
         ]. The mechanisms for the disease manifestations have not been established.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H56374062">
         <span class="h2">
          Primary form
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term primary PAP is used to refer to PAP in which alveolar proteinosis is the main and often only manifestation. It encompasses two etiologies: hereditary and autoimmune, both of which involve disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling:
        </p>
        <p class="headingAnchor" id="H1209843718">
         <span class="h3">
          Hereditary PAP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term hereditary PAP refers specifically to disease caused by abnormalities in the GM-CSF receptor. The term does not encompass congenital PAP, which is also caused by genetic mutations but often presents earlier in life. The GM-CSF receptor is composed of two subunits, encoded by
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F306250&amp;token=87jLzclRwWxNoI%2BQq5Gg7z7xRizZsc%2BPZzCqYC5VD%2B7H0duNBIzBHB8VEPQM2cH6&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RA
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F138981&amp;token=87jLzclRwWxNoI%2BQq5Gg74FqDUUjOx5GUANaW%2FOY4aIN6XTyQQIRpqRH73p1L1kS&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RB
          </i>
         </a>
         , respectively [
         <a href="#rid12">
          12
         </a>
         ]. Mutations in either subunit can affect surfactant catabolism and appear to be a rare cause of PAP in children with autosomal recessive inheritance, described in case reports [
         <a href="#rid13">
          13-15
         </a>
         ]. Unlike the congenital forms of PAP, disease caused by these mutations is usually limited to the alveolar space without affecting the interstitium. Animal models have demonstrated alveolar proteinosis in mice deficient in a subunit of the GM-CSF receptor [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Autoimmune PAP
         </span>
         <span class="headingEndMark">
          —
         </span>
         In adults, and occasionally in older children and adolescents, PAP is an autoimmune disease; antibodies to GM-CSF (anti-GM-CSF) are present in 90 percent of cases. This antibody results in dramatic reduction in surfactant recycling within the alveolar spaces. (See
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"
         </a>
         .)
        </p>
        <p>
         Autoimmune PAP with anti-GM-CSF antibodies is rare in patients younger than 10 years of age [
         <a href="#rid17">
          17
         </a>
         ]. It has been reported in few children who presented in late childhood or adolescence [
         <a href="#rid18">
          18-20
         </a>
         ]. Thus, unlike adults with PAP, the majority of infants and children with PAP do not have the autoimmune form of the disease. As an example, in a study of 15 children with PAP, none had anti-GM-CSF antibodies in the serum and only one had anti-GM-CSF antibodies in bronchoalveolar lavage (BAL) fluid [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Secondary form
         </span>
         <span class="headingEndMark">
          —
         </span>
         As in adults, acquired PAP in children can be seen with the following categories of disorders [
         <a href="#rid22">
          22
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infections
         </strong>
         – eg,
         <em>
          Nocardia
         </em>
         <em>
          asteroides
         </em>
         ,
         <em>
          Mycobacterium
         </em>
         <em>
          tuberculosis
         </em>
         ,
         <em>
          Mycobacterium
         </em>
         <em>
          avium-intracellulare
         </em>
         ,
         <em>
          Pneumocystis
         </em>
         <em>
          jirovecii
         </em>
         , human immunodeficiency virus (HIV), and cytomegalovirus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic malignancies
         </strong>
         <strong>
          and myelodysplastic syndromes
         </strong>
         – Most often lymphoma and leukemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunodeficiencies
         </strong>
         – eg, HIV infection, severe combined immunodeficiency (especially adenosine deaminase deficiency), as well as several genetic immunodeficiencies. Haploinsufficiency of the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F137295&amp;token=tEpDslnpc0F0kICl%2Fz7sFc6jRLzqNN8gxZwGEOirhGlIJ4vKstFoYtwIq96uOKMa&amp;TOPIC_ID=6351" target="_blank">
          <i>
           GATA2
          </i>
         </a>
         gene, which is often associated with a myelodysplastic syndrome, has been described to cause PAP. PAP with hypogammaglobulinemia results from gain-of-function mutations in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F164350&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313VPQn8BF59zzW7T%2FUVB63WO&amp;TOPIC_ID=6351" target="_blank">
          <i>
           OAS1
          </i>
         </a>
         gene, with severe immunodeficiency and PAP presenting in infancy (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F618042&amp;token=tEpDslnpc0F0kICl%2Fz7sFbbHsBJVAXU52QtjSlxi7cXZTNeFUjIx%2F4YoL74r9K2L&amp;TOPIC_ID=6351" target="_blank">
          MIM #618042
         </a>
         ) [
         <a href="#rid23">
          23,24
         </a>
         ]. Hematopoietic stem cell transplantation (HSCT) is considered in select cases with both
         <em>
          GATA2
         </em>
         and
         <em>
          OAS1
         </em>
         mutations. (See
         <a class="medical medical_review" href="/z/d/html/3907.html" rel="external">
          "Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3949.html" rel="external">
          "NK cell deficiency syndromes: Clinical manifestations and diagnosis", section on 'Autosomal dominant GATA2 deficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Solid organ or HSCT
         </strong>
         – Rarely, PAP has been reported following solid organ or HSCT, mediated by immunosuppressive medication [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rheumatologic disease
         </strong>
         – Case reports describe severe PAP in a few children with systemic juvenile idiopathic arthritis (sJIA) [
         <a href="#rid27">
          27
         </a>
         ]. The entity has histopathology consistent with PAP, but, uniquely, there are additional findings of endogenous lipoid pneumonia and an inflammatory profile within the lungs unlike that seen in other forms of PAP. The risk of developing this lung disease seems to be associated with early age of onset of sJIA and having trisomy 21 [
         <a href="#rid28">
          28,29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6413.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhalational exposures
         </strong>
         – eg, to inhaled chemicals (insecticides, fumes) and minerals (silica, aluminum, and titanium).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Idiopathic form
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite the more recent discoveries described above, the etiology of PAP in some infants and children is unclear [
         <a href="#rid21">
          21
         </a>
         ]. In a small subset of infants with pathologic features suggesting a surfactant defect (interstitial expansion, type II epithelial cell hyperplasia, and limited lipoproteinaceous material in the alveolar spaces), no surfactant mutations have been identified. However, because of the similarities in histopathology it is likely that many of these children have defects in intracellular surfactant metabolism that have yet to be discovered. (See
         <a class="local">
          'Congenital form'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction"
         </a>
         .)
        </p>
        <p>
         In older children with PAP who do not have anti-GM-CSF antibodies, the etiology remains unknown. It is possible that some of these children have mutations in
         <em>
          CSF2RA
         </em>
         or
         <em>
          CSF2RB
         </em>
         , as some cases of idiopathic PAP were reported prior to the discovery of these mutations. (See
         <a class="local">
          'Hereditary PAP'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The basic histopathologic characteristic of primary PAP (ie, autoimmune PAP or hereditary PAP due to GM-CSF mutations) is the accumulation of granular, periodic acid-Schiff (PAS) positive, lipoproteinaceous material within the alveoli [
         <a href="#rid22">
          22,30
         </a>
         ]. Large macrophages filled with PAS-positive material are commonly seen in the air spaces. Other abnormalities such as alveolar septal fibrosis or inflammatory reactions are typically absent because the primary defect is in macrophage function rather than type II pneumocytes.
        </p>
        <p>
         The histopathologic characteristics of the congenital forms of PAP are different from the primary form of PAP that is usually seen in adults. The most prominent histopathologic features in these disorders are interstitial widening, type II alveolar cell hyperplasia, and the presence of cholesterol clefts. Accumulation of lipoproteinaceous material in the alveolar spaces (alveolar proteinosis) is also seen, but is less prominent than in primary PAP.
        </p>
        <p>
         On a molecular level, consistent abnormalities in surfactant composition and pulmonary alveolar lipid metabolism have been reported across multiple types of both primary and secondary PAP [
         <a href="#rid31">
          31
         </a>
         ]. Details of histopathologic findings in disorders of surfactant dysfunction are described separately. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Histopathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Signs and symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the congenital forms of PAP, the clinical presentation can range from severe respiratory failure in the neonatal period to more insidious symptoms of chronic interstitial lung disease in older children, including dyspnea, exercise intolerance, cough, and poor growth or weight loss. The phenotype largely depends on the affected gene. (See
         <a class="local">
          'Congenital form'
         </a>
         above.)
        </p>
        <p>
         In infants and younger children with the other forms of PAP, decreased activity may be the initial symptom. Weight loss or failure to gain weight is common. A chronic cough may be present. Hypoxemia is typically noted.
        </p>
        <p>
         The primary presenting symptom in older children and adults is shortness of breath, usually with exercise [
         <a href="#rid22">
          22,32
         </a>
         ]. Cough may be reported, especially in older children and adolescents; typically, it is mild and nonproductive, but, in some cases, it can be prominent and productive of white sputum. Chest pain and hemoptysis may occur but are rare. Fever usually indicates an infection or a different disease. The physical examination may reveal nonspecific manifestations of pulmonary disease, including tachypnea, cyanosis, digital clubbing, and fine crackles. PAP is characterized by a significant discordance between the auscultatory findings, which are minimal or absent, and the radiographic findings, which include extensive infiltrates.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chest radiographs of adults with autoimmune PAP typically show bilateral alveolar filling pattern [
         <a href="#rid32">
          32-34
         </a>
         ]. The infiltrates are often more prominent in the perihilar regions, resembling the "butterfly" or "bat wing" appearance of pulmonary edema but without cardiomegaly. (see
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults", section on 'Imaging'
         </a>
         ). This same pattern may be seen in those with hereditary PAP.
        </p>
        <p>
         The radiographic features of infants and children with congenital PAP are more diffuse and are typical of interstitial lung disease. Chest films typically show bilateral ground-glass densities and increased interstitial markings.
        </p>
        <p>
         High-resolution computed tomography (HRCT) is recommended in the evaluation of all young children with diffuse lung disease, including children with suspected PAP [
         <a href="#rid35">
          35
         </a>
         ]. In children with primary PAP, HRCT shows ground-glass opacities of alveolar spaces and thickening of the interlobular and intralobular septa in typical polygonal shapes called "crazy paving" [
         <a href="#rid22">
          22,36
         </a>
         ]. Children with congenital PAP typically have a more heterogenous pattern, some with crazy paving and others more resembling nonspecific interstitial pneumonia. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Radiographic studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common abnormalities in pulmonary function tests are a restrictive pattern and a reduction in the diffusing capacity for carbon monoxide [
         <a href="#rid32">
          32
         </a>
         ]. The arterial partial pressure of oxygen (PaO
         <sub>
          2
         </sub>
         ) and oxygen saturation values are generally low, with a low partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) and normal pH. Alveolar-arterial PO
         <sub>
          2
         </sub>
         difference is high, and the shunt fraction, while breathing 100 percent oxygen, typically is elevated [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         The clinical presentation of PAP in adults is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4373.html" rel="external">
          "Causes, clinical manifestations, and diagnosis of pulmonary alveolar proteinosis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H801118961">
         <span class="h2">
          Approach by age group
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &lt;2 years old
         </strong>
         – In infants and children &lt;2 years of age with suspected PAP, the specific cause of the PAP is generally made by genetic testing for congenital forms of PAP (inborn errors of surfactant metabolism and lysinuric protein intolerance [LPI]) (see
         <a class="local">
          'Laboratory tests'
         </a>
         below). Genetic testing is indicated for patients with
         <strong>
          any
         </strong>
         of the following [
         <a href="#rid35">
          35
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe unexplained lung disease in the newborn period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diffuse disease involving the entire lung on high-resolution CT (HRCT).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If lung biopsy is performed, histopathology that demonstrates findings of congenital PAP, desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia (NSIP), or chronic pneumonitis of infancy (CPI). (See
         <a class="medical medical_review" href="/z/d/html/6381.html" rel="external">
          "Classification of diffuse lung disease (interstitial lung disease) in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electron microscopy (EM) demonstrating abnormal or absent lamellar bodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &gt;2 years old
         </strong>
         – In older children, the diagnosis of PAP is usually raised during the course of an evaluation for the nonspecific clinical symptoms described above. The diagnosis of PAP is suggested by radiographic findings and confirmed by bronchoscopy (see
         <a class="local">
          'Imaging'
         </a>
         above and
         <a class="local">
          'Bronchoscopy'
         </a>
         below). Lung biopsy may be informative if the diagnosis remains uncertain (see
         <a class="local">
          'Lung biopsy'
         </a>
         below). The specific
         <strong>
          cause
         </strong>
         of the PAP may be identified by laboratory testing, as outlined below. (See
         <a class="local">
          'Laboratory tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Laboratory tests
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &lt;2 years old
         </strong>
         – Infants and young children with suspected congenital PAP should undergo genetic testing for an inborn error of surfactant metabolism (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178640&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWBYvxs5%2BwVZVSC5f9ekAfQ7&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPB
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178620&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWA5xwZuJaSzQofzVsf1R0ZE&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPC
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601615&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAvN5Ym0VFBwBqjZPN6uIc&amp;TOPIC_ID=6351" target="_blank">
          <i>
           ABCA3
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=6351" target="_blank">
          <i>
           NKX2.1
          </i>
          /
          <i>
           TTF1
          </i>
         </a>
         genes) [
         <a href="#rid35">
          35
         </a>
         ]; lysinuric protein intolerance (LPI;
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603593&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypPLCxuS%2Fh96C9M4Y0WASei&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SLC7A7
          </i>
         </a>
         gene), and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F164350&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313VPQn8BF59zzW7T%2FUVB63WO&amp;TOPIC_ID=6351" target="_blank">
          <i>
           OAS1
          </i>
         </a>
         <em>
         </em>
         mutations. These genes can be tested simultaneously using panels designed to detect genetic causes of pulmonary disease. A
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Ftests%2F%3Fterm%3DCN262422%26filter%3Dtesttype%3Aclinical&amp;token=aJfTgXyKQXTdKZBj%2BfE2zwA5cTihMAxa44K95cZsv%2BISNKraUphXNc%2BTsjc%2Fkg7SrkRx3R%2BofL22hc7d4bzaj7kGuAPqFsLDOJAisil%2BZ2gXNUFRX6AgjSN%2F1AA0KvK7&amp;TOPIC_ID=6351" target="_blank">
          list of panels
         </a>
         is available at the Genetic Testing Registry website. Some patients with inborn errors of surfactant metabolism may not be successfully diagnosed by genetic testing, necessitating open lung biopsy [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="local">
          'Congenital form'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &gt;2 years old
         </strong>
         – PAP in children &gt;2 years is most likely to be a noncongenital form. Laboratory testing should include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antibodies to granulocyte-macrophage colony-stimulating factor (anti-GM-CSF) – This test is highly sensitive for autoimmune PAP. Testing is commercially available. Importantly, despite high sensitivity, the test has limited specificity for detecting autoimmune PAP. Anti-GM-CSF antibodies may be present in patients with autoinflammatory diseases such as inflammatory bowel disease or malignancies and have been reported in pooled immunoglobulin products [
         <a href="#rid2">
          2,38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F306250&amp;token=87jLzclRwWxNoI%2BQq5Gg7z7xRizZsc%2BPZzCqYC5VD%2B7H0duNBIzBHB8VEPQM2cH6&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RA
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F138981&amp;token=87jLzclRwWxNoI%2BQq5Gg74FqDUUjOx5GUANaW%2FOY4aIN6XTyQQIRpqRH73p1L1kS&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RB
          </i>
         </a>
         <em>
         </em>
         sequencing should be performed to evaluate for hereditary PAP (due to GM-CSF receptor mutations); these genes are typically included in testing panels designed to detect genetic causes of interstitial lung disease. Testing for congenital PAP should also be performed because some types occasionally present after infancy. (See
         <a class="local">
          'Congenital form'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Evaluation for possible causes of secondary PAP (if suggested by the clinical picture):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematologic malignancy and myelodysplastic syndrome (see
         <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">
          "Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Connective tissue disorders (see
         <a class="medical medical_review" href="/z/d/html/6381.html" rel="external">
          "Classification of diffuse lung disease (interstitial lung disease) in infants and children", section on 'Disorders related to systemic disease processes'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Congenital or acquired immunodeficiency (see
         <a class="medical medical_review" href="/z/d/html/5949.html" rel="external">
          "Approach to the child with recurrent infections"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Bronchoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoscopy with bronchoalveolar lavage (BAL) may be helpful for diagnosis in a subset of patients with possible PAP:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In young children with diffuse lung disease of unknown cause, or with possible immunodeficiency, bronchoscopy may be informative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In individuals with noncongenital forms of PAP, BAL typically yields a turbid and milky effluent [
         <a href="#rid34">
          34
         </a>
         ], which decreases in turbidity as serial lavages are performed. Examination of the sediment using light microscopy reveals large amounts of amorphous, lipoproteinaceous material that stains brightly positive with periodic acid-Schiff (PAS); large foamy macrophages may also be seen [
         <a href="#rid22">
          22,30,32
         </a>
         ]. The differential cell count of BAL fluid shows macrophage predominance without inflammatory cells. These findings support the diagnosis of PAP but further tests are required to determine its specific cause. EM is not routinely needed for diagnosis but can be helpful in validating the light microscopy findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children presenting with respiratory failure at birth due to presumed surfactant dysfunction, there may be little role for bronchoscopy due to the size of the patient and because the diagnosis often can be established through imaging and genetic testing.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although genetic testing is the gold standard for the diagnosis of the congenital forms of PAP, lung biopsy can be useful in certain circumstances. In the neonate with respiratory failure, genetic testing that takes up to four weeks or longer may delay timely diagnosis and referral for lung transplantation. In this case, lung biopsy can be strongly suggestive of an inborn error of surfactant metabolism, especially if abnormal lamellar bodies are demonstrated. Also, some children have a lung biopsy consistent with an inborn error of surfactant metabolism, but no mutations are found. This suggests that there are mutations in other genes associated with surfactant metabolism that have yet to be discovered. (See
         <a class="local">
          'Idiopathic form'
         </a>
         above.)
        </p>
        <p>
         For patients with suspected noncongenital PAP and without anti-GM-CSF antibodies, a provisional diagnosis often can be made based on clinical presentation and HRCT and BAL findings, but histologic confirmation is often required. Studies in adults show that transbronchial biopsies are as reliable as open lung biopsies in establishing the diagnosis of PAP and should be utilized more often [
         <a href="#rid22">
          22
         </a>
         ]. The diagnostic findings of PAP are accumulation of PAS-positive, lipoproteinaceous material in air spaces of otherwise preserved lung tissue. Similar yield of transbronchial biopsies in children has not been demonstrated and may also be limited by the size of equipment that can be used in smaller patients.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         PAP is rare in children and patients are generally referred to a specialist for diagnosis and management. Treatment decisions depend on the cause and severity in the individual patient, as outlined below.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Congenital PAP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of congenital PAP depends on the genetic cause:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surfactant dysfunction disorder
         </strong>
         – For individuals with a surfactant dysfunction disorder (due to variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178640&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWBYvxs5%2BwVZVSC5f9ekAfQ7&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPB
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178620&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWA5xwZuJaSzQofzVsf1R0ZE&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPC
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601615&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAvN5Ym0VFBwBqjZPN6uIc&amp;TOPIC_ID=6351" target="_blank">
          <i>
           ABCA3
          </i>
         </a>
         , or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=6351" target="_blank">
          <i>
           NKX2.1
          </i>
          /
          <i>
           TTF1
          </i>
         </a>
         ), treatment with exogenous surfactant therapy and whole lung lavage (WLL) are ineffective, despite the presence of PAP histologically [
         <a href="#rid39">
          39
         </a>
         ]. Management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lysinuric protein intolerance (LPI)
         </strong>
         – For individuals with LPI (due to variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603593&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypPLCxuS%2Fh96C9M4Y0WASei&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SLC7A7
          </i>
         </a>
         ), treatment consists of a protein-restricted diet and supplementation with oral citrulline and nitrogen-scavenging drugs [
         <a href="#rid5">
          5
         </a>
         ]. Lung transplantation is contraindicated for children with LPI and end-stage lung disease because fatal recurrence in the transplanted lung has been reported [
         <a href="#rid6">
          6
         </a>
         ]. Improvement with WLL has been reported in one case [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           MARS1
          </em>
         </strong>
         <strong>
          -related disease
         </strong>
         – Treatment is largely supportive. Case reports suggest improvement with high protein intake and judicious methionine supplementation [
         <a href="#rid41">
          41,42
         </a>
         ]. WLL may provide transient benefit [
         <a href="#rid11">
          11,42
         </a>
         ]. (See
         <a class="local">
          'Whole lung lavage'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Primary and secondary PAP
         </span>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Whole lung lavage
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary PAP
         </strong>
         – For individuals with primary PAP (ie, autoimmune PAP or hereditary PAP) and moderate to severe respiratory symptoms, we recommend treatment with large-volume WLL.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         WLL is the primary treatment used for adults with autoimmune PAP. WLL generally leads to prompt improvement in symptoms and measures of lung function, and permanent remission in many of these patients [
         <a href="#rid43">
          43,44
         </a>
         ]. Based on this clinical experience in adults, WLL is recommended for pediatric patients with documented autoimmune PAP (antibodies to granulocyte-macrophage colony-stimulating factor [GM-CSF]) and moderate or severe symptoms, although outcomes in this age group are limited to a few case reports [
         <a href="#rid18">
          18,45,46
         </a>
         ]. Similarly, WLL is suggested for patients with hereditary PAP (due to GM-CSF receptor mutations) based on positive outcomes from a few case reports [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults", section on 'Whole lung lavage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other forms of PAP
         </strong>
         – Outside of primary PAP, the efficacy of WLL is unclear and the procedure should be undertaken with caution. Although case reports describe mixed outcomes of WLL in pediatric patients with PAP, many of these reports are older and do not distinguish among the different causes of PAP [
         <a href="#rid33">
          33,34,47-49
         </a>
         ]. For those with surfactant function disorders, WLL is rarely effective and may pose substantial risk for those with severe respiratory disease. For other forms of congenital PAP (LPI or
         <em>
          MARS1
         </em>
         -related disease), a few case reports suggest that WLL may provide transient relief.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with secondary PAP (eg, due to hematologic or immunologic disease), treatment of the underlying disorder is the mainstay of therapy, but WLL may improve pulmonary symptoms pending treatment of the underlying disorder, such as in rheumatologic disease [
         <a href="#rid50">
          50,51
         </a>
         ]. For patients with idiopathic PAP, it is reasonable to do a trial of WLL for those suffering from respiratory distress or the debilitating effects of the disease (ie, exercise intolerance, poor growth, and pulmonary hypertension). If there is a question of possible benefit in a particular subject, lavage of a single lobe can be considered as a test of benefit with the advantage of a shorter procedural time.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – In older children and adults, a double lumen endotracheal tube is used to ventilate one lung while lavaging the other. In young children, the small caliber of the airway poses a major obstacle. There is considerable variability in the technical performance of WLL across centers [
         <a href="#rid52">
          52
         </a>
         ]. In some of these cases, partial or WLL has been accomplished using standard endotracheal tube intubation and hyperbaric oxygen [
         <a href="#rid49">
          49
         </a>
         ] and combined intubation and flexible bronchoscopy [
         <a href="#rid34">
          34
         </a>
         ]. Alternative approaches utilizing two endotracheal tubes simultaneously have been described [
         <a href="#rid53">
          53
         </a>
         ]. In other cases, lavage has been successfully performed during extracorporeal oxygenation [
         <a href="#rid33">
          33,47,48
         </a>
         ]. In general, the objective is to lavage repeatedly until the recovered fluid contains little sedimentable material [
         <a href="#rid47">
          47
         </a>
         ]. Improvement of clinical symptoms and arterial partial pressure of oxygen (PaO
         <sub>
          2
         </sub>
         ) is usually achieved within one to several days. Resolution of pulmonary infiltrates on chest radiographs or CT scans may take longer. (See
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults", section on 'Whole lung lavage'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         WLL should be performed in a center with both bronchoscopic and anesthetic experience with the procedure; this may require referral to a center where such expertise is available.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3512091938">
         <span class="h3">
          Second-line therapies for selected patients
         </span>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h4">
          Recombinant GM-CSF
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with autoimmune PAP with poor response to WLL alone, we suggest a trial of inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), in addition to WLL. This is based upon indirect evidence from case series of its use in adults with autoimmune PAP and because reduced GM-CSF function is thought to play a role in some forms of PAP. This therapy has also been used in some children with autoimmune PAP, with variable success [
         <a href="#rid18">
          18-20,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults", section on 'Recombinant GM-CSF'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H354005354">
         <span class="h4">
          Lung transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For infants with severe congenital PAP due to
         <em>
          SFTPB
         </em>
         ,
         <em>
          SFTPC
         </em>
         ,
         <em>
          ABCA3
         </em>
         , or
         <em>
          NKX2.1
         </em>
         -related
         <em>
         </em>
         disease, lung transplantation is appropriate and effective, as described above [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Lung transplantation'
         </a>
         .)
        </p>
        <p>
         By contrast, for patients with autoimmune PAP or hereditary PAP (due to
         <em>
          CSF2RA
         </em>
         or
         <em>
          CSF2RB
         </em>
         mutations), limited case reports suggest that transplantation is
         <strong>
          not
         </strong>
         an appropriate therapy. There is also concern that autoimmune disease could recur in transplanted new lungs. In hereditary PAP, recurrence has been reported in a patient with disease due to a
         <em>
          CSF2RB
         </em>
         mutation, thought to be mediated through bone marrow-derived macrophages [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1011956307">
         <span class="h4">
          Hematopoietic stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe hereditary PAP due to GM-CSF receptor dysfunction may be candidates for hematopoietic stem cell transplantation (HSCT). Case reports describe successful use of HSCT in this population, with improvement in lung disease following engraftment [
         <a href="#rid57">
          57,58
         </a>
         ]. By contrast, lung transplantation may not be useful for this disorder, because it stems from a mutation involving bone marrow-derived cells and may recur after lung transplantation (as described above).
        </p>
        <p class="headingAnchor" id="H4253755911">
         <span class="h3">
          Unproven therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunomodulatory therapies
         </strong>
         – Additional immunomodulatory treatments have been utilized in adults with refractory autoimmune PAP, including
         <a class="drug drug_pediatric" data-topicid="12971" href="/z/d/drug information/12971.html" rel="external">
          rituximab
         </a>
         and plasmapheresis. Outcomes are variable. There are no trials or case reports utilizing these therapies in children. Nevertheless, consideration of such treatments may be warranted in the rare child with refractory autoimmune disease. (See
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults", section on 'Refractory disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiinflammatory therapies
         </strong>
         – In infants and children with PAP caused by
         <em>
          SFTPC
         </em>
         and
         <em>
          ABCA3
         </em>
         mutations, antiinflammatory therapy (eg, corticosteroids,
         <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">
          hydroxychloroquine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">
          azithromycin
         </a>
         ) has been suggested [
         <a href="#rid59">
          59,60
         </a>
         ], but whether these treatments provide clinical benefit is unclear. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Pharmacologic therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For other forms of PAP, there is no information about the utility of antiinflammatory therapy and there are reports that suggest it may be harmful in certain cases [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Investigational approaches
         </strong>
         – Pulmonary macrophage transplantation for hereditary PAP has shown to improve lung manifestations in a murine model. This might be a promising therapy for children with this disease in the future [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, multiple lines of research point to a role for disrupted lipid metabolism and cholesterol homeostasis in the pathogenesis of some forms of PAP, suggesting multiple potential treatment pathways [
         <a href="#rid31">
          31,64
         </a>
         ]. Investigations into both statins and thiazolidinediones as treatment for PAP are ongoing. One notable report described two cases of adults with autoimmune PAP who had clinical improvement following initiation of statin therapy for comorbid hypercholesterolemia [
         <a href="#rid65">
          65
         </a>
         ]. Further in vitro testing demonstrated modulation of the lipid content within foamy macrophages upon exposure to statins, and a murine model of PAP utilizing a
         <em>
          CSF2RB
         </em>
         knock-out also responded to statin treatment. No data exist regarding the use of statins for PAP in children. Given the apparent effect of statins in patients with autoimmune disease as well as an animal model of hereditary PAP, there may be a role for statins in children with autoimmune PAP as well as those with hereditary PAP due to
         <em>
          CSF2RA
         </em>
         or
         <em>
          CSF2RB
         </em>
         mutations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis in congenital PAP differs depending on the causative genetic mutation; lung transplantation is a common consideration for severe forms of these disorders. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction"
         </a>
         .)
        </p>
        <p>
         Children with hereditary PAP (due to mutations in the GM-CSF receptor) often have severe, progressive lung disease, but unlike the congenital forms of the disease, they may respond to whole lung lavage (WLL). The prognosis for these patients may also evolve in the coming years with emerging therapies. (See
         <a class="local">
          'Unproven therapies'
         </a>
         above.)
        </p>
        <p>
         Autoimmune or idiopathic forms of PAP carry a variable prognosis in children, as in adults. Spontaneous remission or long-term resolution of symptoms after a single lavage has been reported [
         <a href="#rid32">
          32,48,66
         </a>
         ]. Some patients may require repeated lavages, as often as every few months. Deterioration of respiratory status despite repeated lavages may occur, resulting in death [
         <a href="#rid32">
          32-34,47
         </a>
         ]. Recurrence of PAP has been reported after lung transplantation. Prognosis in secondary PAP is closely related to the course of the underlying primary disease process. (See
         <a class="medical medical_review" href="/z/d/html/4356.html" rel="external">
          "Treatment and prognosis of pulmonary alveolar proteinosis in adults", section on 'Prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and pathogenesis
         </strong>
         – Pulmonary alveolar proteinosis (PAP) is an uncommon disorder characterized by the accumulation of lipoproteinaceous pulmonary surfactants within alveoli, due to altered surfactant production, removal, or both. Four forms of PAP are recognized in children: congenital, primary, secondary, and idiopathic  (
         <a class="graphic graphic_table graphicRef77313" href="/z/d/graphic/77313.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef115856" href="/z/d/graphic/115856.html" rel="external">
          figure 1
         </a>
         ). Age at onset and clinical presentation can help to differentiate these forms. These are all rare conditions and are generally referred to a specialist for diagnosis and management. Treatment decisions depend on the underlying cause and severity of symptoms. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants &lt;2 years
         </strong>
         – The congenital form of PAP is usually caused by inborn errors of surfactant metabolism (variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178640&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWBYvxs5%2BwVZVSC5f9ekAfQ7&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPB
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F178620&amp;token=tEpDslnpc0F0kICl%2Fz7sFeJEtfajUCPcRjYRwn%2FUxWA5xwZuJaSzQofzVsf1R0ZE&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SFTPC
          </i>
         </a>
         ,
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F601615&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqAvN5Ym0VFBwBqjZPN6uIc&amp;TOPIC_ID=6351" target="_blank">
          <i>
           ABCA3
          </i>
         </a>
         , or
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=6351" target="_blank">
          <i>
           NKX2.1
          </i>
          /
          <i>
           TTF1
          </i>
         </a>
         ) or by a defect in the plasma membrane transport of cationic amino acids (known as lysinuric protein intolerance [LPI], caused by variants in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F603593&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdypPLCxuS%2Fh96C9M4Y0WASei&amp;TOPIC_ID=6351" target="_blank">
          <i>
           SLC7A7
          </i>
         </a>
         gene).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical presentation and diagnosis
         </strong>
         – Congenital PAP usually presents in the neonatal period or within the first one to two years of life; some patients may have a more insidious or delayed onset. High-resolution CT (HRCT) reveals diffuse disease involving the entire lung. Even when PAP is present in these disorders, interstitial pathology is the primary morbidity. The diagnosis is made by genetic testing, usually with a gene panel. (See
         <a class="local">
          'Congenital form'
         </a>
         above and
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Management
         </strong>
         – For neonates with severe congenital PAP due to
         <em>
          SFTPB
         </em>
         ,
         <em>
          SFTPC
         </em>
         ,
         <em>
          ABCA3
         </em>
         , or
         <em>
          NKX2.1
         </em>
         gene mutations, lung transplantation is the only treatment that appears to improve outcome. Exogenous surfactant therapy or whole lung lavage (WLL) are ineffective and may well be injurious to the patient. (See
         <a class="medical medical_review" href="/z/d/html/14371.html" rel="external">
          "Genetic disorders of surfactant dysfunction", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For individuals with LPI, treatment consists of a protein-restricted diet and supplementation with oral citrulline. Lung transplantation is contraindicated. (See
         <a class="local">
          'Congenital PAP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Children &gt;2 years
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical presentation
         </strong>
         – In children who present after infancy, the possibility of PAP is usually raised during the course of an evaluation for nonspecific symptoms and signs of pulmonary disease. The diagnosis is suggested by radiographic findings and confirmed by bronchoscopy with bronchoalveolar lavage (BAL) and/or lung biopsy. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Genetic and laboratory testing identifies the type of PAP and informs management:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Primary PAP
         </strong>
         – Primary PAP refers to PAP in which alveolar proteinosis is the main and often only histopathologic manifestation. It encompasses two etiologies, both of which involve disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hereditary
         </strong>
         – Hereditary PAP is a rare form of PAP that tends to present after infancy and is caused by pathogenic variants in the GM-CSF receptor. The histopathology typically involves only the alveolar spaces, with minimal interstitial disease. The diagnosis is made by genetic testing for variants in
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F306250&amp;token=87jLzclRwWxNoI%2BQq5Gg7z7xRizZsc%2BPZzCqYC5VD%2B7H0duNBIzBHB8VEPQM2cH6&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RA
          </i>
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F138981&amp;token=87jLzclRwWxNoI%2BQq5Gg74FqDUUjOx5GUANaW%2FOY4aIN6XTyQQIRpqRH73p1L1kS&amp;TOPIC_ID=6351" target="_blank">
          <i>
           CSF2RB
          </i>
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Single or serial WLL is typically effective in these patients, based on case reports. Hematopoietic stem cell transplant (HSCT) may be a consideration in refractory cases. (See
         <a class="local">
          'Hereditary PAP'
         </a>
         above and
         <a class="local">
          'Hematopoietic stem cell transplantation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Autoimmune
         </strong>
         – Autoimmune PAP is mediated by anti-GM-CSF antibodies. This form accounts for the majority of PAP cases in adults; it is rare in children but may occur in older children and adolescents. The diagnosis is confirmed by testing for anti-GM-CSF antibodies. (See
         <a class="local">
          'Autoimmune PAP'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         For pediatric patients with confirmed autoimmune PAP (anti-GM-CSF antibody positive) and moderate to severe symptoms, we recommend WLL (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). This is based primarily on observational reports in adults with moderate to severe respiratory impairment due to autoimmune PAP, in whom WLL generally leads to prompt improvement in symptoms and measures of lung function and permanent remission in many of these patients, with few adverse effects. Anesthetic and procedural challenges are significant (see
         <a class="local">
          'Whole lung lavage'
         </a>
         above). For those with poor response to WLL, we suggest a trial of adjuvant therapy with inhaled recombinant GM-CSF, based on indirect evidence from adults (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Recombinant GM-CSF'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Secondary PAP
         </strong>
         – Secondary PAP refers to PAP that occurs in the setting of an underlying systemic disease. Even in patients without obvious extrapulmonary disease, secondary PAP due to immunodeficiency, malignancy, or connective tissue disease should be considered in the evaluation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For secondary PAP, treatment of the underlying disorder is the mainstay of therapy. For patients with severe pulmonary involvement, it is reasonable to do a trial of WLL in an attempt to achieve more rapid improvement in symptoms. (See
         <a class="local">
          'Secondary form'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1450738493">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Timothy J Vece, MD, Leland L Fan, MD, Okan Elidemir, MD, and Manuel Silva Carmona, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hamvas A, Cole FS, Nogee LM. Genetic disorders of surfactant proteins. Neonatology 2007; 91:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griese M. Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy C, Avetisyan R, Carey BC, et al. Prevalence and healthcare burden of pulmonary alveolar proteinosis. Orphanet J Rare Dis 2018; 13:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamaria F, Parenti G, Guidi G, et al. Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med 1996; 153:731.
          </a>
         </li>
         <li class="breakAll">
          Nunes V, Niinikoski H. Lysinuric Protein Intolerance. 2006 Dec 21 [Updated 2018 Apr 12]. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1361/ (Accessed on May 05, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parenti G, Sebastio G, Strisciuglio P, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr 1995; 126:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauhin W, Habarou F, Gobin S, et al. Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood. Orphanet J Rare Dis 2017; 12:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valimahamed-Mitha S, Berteloot L, Ducoin H, et al. Lung involvement in children with lysinuric protein intolerance. J Inherit Metab Dis 2015; 38:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadchouel A, Wieland T, Griese M, et al. Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island. Am J Hum Genet 2015; 96:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enaud L, Hadchouel A, Coulomb A, et al. Pulmonary alveolar proteinosis in children on La Réunion Island: a new inherited disorder? Orphanet J Rare Dis 2014; 9:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashida K, Kitamura T, Gorman DM, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A 1990; 87:9655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010; 182:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu CY, Su SC, Fan WL, et al. Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption. Sci Rep 2017; 7:43469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J 2011; 37:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto H, Yamaguchi E, Agata H, et al. A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis. Pediatr Pulmonol 2008; 43:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson TE, Trapnell BC, Goris ML, et al. Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis. Chest 2009; 135:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price A, Manson D, Cutz E, Dell S. Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF. Pediatr Pulmonol 2006; 41:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latzin P, Tredano M, Wüst Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis. A review and an update. Chest 1997; 111:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho K, Yamada M, Agematsu K, et al. Heterozygous Mutations in OAS1 Cause Infantile-Onset Pulmonary Alveolar Proteinosis with Hypogammaglobulinemia. Am J Hum Genet 2018; 102:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magg T, Okano T, Koenig LM, et al. Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency. Sci Immunol 2021; 6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darley DR, Malouf MA, Glanville AR. A rare case of everolimus-induced pulmonary alveolar proteinosis. J Heart Lung Transplant 2016; 35:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasan A, Ram R, Swamy T. Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient. Lung India 2014; 31:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulert GS, Yasin S, Carey B, et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol 2019; 71:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ROSEN SH, CASTLEMAN B, LIEBOW AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griese M, Bonella F, Costabel U, et al. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis. Am J Respir Crit Care Med 2019; 200:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahut B, Delacourt C, Scheinmann P, et al. Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review. Pediatrics 1996; 97:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazyck EM, Bonner JT, Herd HM, Symbas PN. Pulmonary lavage for childhood pulmonary alveolar proteinosis. J Pediatr 1972; 80:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahut B, de Blic J, Le Bourgeois M, et al. Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis. Pediatr Pulmonol 1992; 13:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am J Respir Crit Care Med 2013; 188:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berteloot L, Taam RA, Emond-Gonsard S, et al. Primary pulmonary alveolar proteinosis: computed tomography features at diagnosis. Pediatr Radiol 2014; 44:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gower WA, Wert SE, Ginsberg JS, et al. Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. J Pediatr 2010; 157:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svenson M, Hansen MB, Ross C, et al. Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998; 91:2054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994; 125:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceruti M, Rodi G, Stella GM, et al. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis 2007; 2:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rips J, Meyer-Schuman R, Breuer O, et al. MARS variant associated with both recessive interstitial lung and liver disease and dominant Charcot-Marie-Tooth disease. Eur J Med Genet 2018; 61:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lenz D, Stahl M, Seidl E, et al. Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic MARS1 variants. Pediatr Pulmonol 2020; 55:3057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao YY, Huang H, Liu YZ, et al. Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long-term Follow-up Study. Chin Med J (Engl) 2015; 128:2714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Awab A, Khan MS, Youness HA. Whole lung lavage-technical details, challenges and management of complications. J Thorac Dis 2017; 9:1697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trukalj M, Perica M, Ferenčić Ž, et al. Successful Treatment of Autoimmune Pulmonary Alveolar Proteinosis in a Pediatric Patient. Am J Case Rep 2016; 17:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiratzka LF, Swan DM, Rose EF, Ahrens RC. Bilateral simultaneous lung lavage utilizing membrane oxygenator for pulmonary alveolar proteinosis in an 8-month-old infant. Ann Thorac Surg 1983; 35:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seard C, Wasserman K, Benfield JR, et al. Simultaneous bilateral lung lavage (alveolar washing) using partial cardiopulmonary bypass. Am Rev Respir Dis 1970; 101:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spock A. Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage. Eur Respir J 2005; 25:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsukahara K, Lindell RB, Newman H, et al. Successful whole lung lavage in a child with pulmonary alveolar proteinosis secondary to hematologic malignancy. Pediatr Pulmonol 2022; 57:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidl E, Schramm D, Schön C, et al. Pulmonary alveolar proteinosis due to heterozygous mutation in OAS1: Whole lung lavages for long-term bridging to hematopoietic stem cell transplantation. Pediatr Pulmonol 2022; 57:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campo I, Luisetti M, Griese M, et al. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures. Orphanet J Rare Dis 2016; 11:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaushal B, Chauhan S, Hasija S. Bilateral whole lung lavage by lung isolation in a child with pulmonary alveolar proteinosis: A new technique. Ann Card Anaesth 2021; 24:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gajewska ME, Sritharan SS, Santoni-Rugiu E, Bendstrup EM. Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim). Respir Med Case Rep 2018; 23:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eldridge WB, Zhang Q, Faro A, et al. Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism. J Pediatr 2017; 184:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takaki M, Tanaka T, Komohara Y, et al. Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB. Respir Med Case Rep 2016; 19:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozcelik U, Aytac S, Kuskonmaz B, et al. Nonmyeloablative hematopoietic stem cell transplantation in a patient with hereditary pulmonary alveolar proteinosis. Pediatr Pulmonol 2021; 56:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frémond ML, Hadchouel A, Schweitzer C, et al. Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency. Thorax 2018; 73:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005; 352:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush A, Cunningham S, de Blic J, et al. European protocols for the diagnosis and initial treatment of interstitial lung disease in children. Thorax 2015; 70:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akasaka K, Tanaka T, Kitamura N, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med 2015; 15:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Arumugam P, Sakagami T, et al. Pulmonary macrophage transplantation therapy. Nature 2014; 514:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Happle C, Lachmann N, Ackermann M, et al. Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis. Am J Respir Crit Care Med 2018; 198:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallese A, Suzuki T, McCarthy C, et al. Targeting cholesterol homeostasis in lung diseases. Sci Rep 2017; 7:10211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy C, Lee E, Bridges JP, et al. Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis. Nat Commun 2018; 9:3127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul K, Müller KM, Oppermann HC, Nützenadel W. Pulmonary alveolar lipoproteinosis in a seven-year-old girl. A follow-up over six years. Acta Paediatr Scand 1991; 80:477.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6351 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17575475" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Genetic disorders of surfactant proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28771412" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary Alveolar Proteinosis: A Comprehensive Clinical Perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30064481" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence and healthcare burden of pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8564125" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8564125" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289783" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7844671" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28057010" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25335805" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lung involvement in children with lysinuric protein intolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25913036" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24927752" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Pulmonary alveolar proteinosis in children on La Réunion Island: a new inherited disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1702217" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20622029" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28233860" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Whole-Genome Sequencing of a Family with Hereditary Pulmonary Alveolar Proteinosis Identifies a Rare Structural Variant Involving CSF2RA/CRLF2/IL3RA Gene Disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21205713" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7697542" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18202348" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18618617" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A combination therapy of whole lung lavage and GM-CSF inhalation in pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19265094" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Quantitative analysis of longitudinal response to aerosolized granulocyte-macrophage colony-stimulating factor in two adolescents with autoimmune pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16475176" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pulmonary alveolar proteinosis associated with anti-GM-CSF antibodies in a child: successful treatment with inhaled GM-CSF.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15618581" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041997" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Diagnosing pulmonary alveolar proteinosis. A review and an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29455859" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Heterozygous Mutations in OAS1 Cause Infantile-Onset Pulmonary Alveolar Proteinosis with Hypogammaglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34145065" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26525403" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : A rare case of everolimus-induced pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25125821" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23139240" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31379071" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31562126" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Emergent high fatality lung disease in systemic juvenile arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13552931" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002528" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Quantitative Lipidomics in Pulmonary Alveolar Proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8545205" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pulmonary alveolar proteinosis: experience with eight pediatric cases and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5018397" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pulmonary lavage for childhood pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1589314" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Partial and massive lung lavages in an infant with severe pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23905526" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24599270" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Primary pulmonary alveolar proteinosis: computed tomography features at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20304423" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9490690" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8071741" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17386098" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29655802" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : MARS variant associated with both recessive interstitial lung and liver disease and dominant Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32833345" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Rescue of respiratory failure in pulmonary alveolar proteinosis due to pathogenic MARS1 variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26481735" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Whole Lung Lavage Treatment of Chinese Patients with Autoimmune Pulmonary Alveolar Proteinosis: A Retrospective Long-term Follow-up Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28740686" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Whole lung lavage-technical details, challenges and management of complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18955567" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27592713" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Successful Treatment of Autoimmune Pulmonary Alveolar Proteinosis in a Pediatric Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6830367" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Bilateral simultaneous lung lavage utilizing membrane oxygenator for pulmonary alveolar proteinosis in an 8-month-old infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5419972" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Simultaneous bilateral lung lavage (alveolar washing) using partial cardiopulmonary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15929971" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Long-term survival of paediatric patients with pulmonary alveolar proteinosis treated with lung lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34644455" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Successful whole lung lavage in a child with pulmonary alveolar proteinosis secondary to hematologic malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34647697" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Pulmonary alveolar proteinosis due to heterozygous mutation in OAS1: Whole lung lavages for long-term bridging to hematopoietic stem cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27577926" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33884993" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Bilateral whole lung lavage by lung isolation in a child with pulmonary alveolar proteinosis: A new technique.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29719809" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Autoimmune pulmonary alveolar proteinosis in an adolescent successfully treated with inhaled rhGM-CSF (molgramostim).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28215425" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Outcomes of Lung Transplantation for Infants and Children with Genetic Disorders of Surfactant Metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27595063" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Recurrence of pulmonary alveolar proteinosis after bilateral lung transplantation in a patient with a nonsense mutation in CSF2RB.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33232559" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Nonmyeloablative hematopoietic stem cell transplantation in a patient with hereditary pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29263235" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Successful haematopoietic stem cell transplantation in a case of pulmonary alveolar proteinosis due to GM-CSF receptor deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647591" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Hydroxychloroquine and surfactant protein C deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26135832" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : European protocols for the diagnosis and initial treatment of interstitial lung disease in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26264717" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25274301" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Pulmonary macrophage transplantation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29652170" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28860566" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Targeting cholesterol homeostasis in lung diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30087322" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2058401" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pulmonary alveolar lipoproteinosis in a seven-year-old girl. A follow-up over six years.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
